Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

@article{Cipriani2009ComparativeEA,
  title={Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis},
  author={Andrea Cipriani and Toshiaki Furukawa and Georgia Salanti and John R. Geddes and Julian P. T. Higgins and Rachel Churchill and Norio Watanabe and Atsuo Nakagawa and Ichiro M. Omori and Hugh McGuire and Michele Tansella and Corrado Barbui},
  journal={The Lancet},
  year={2009},
  volume={373},
  pages={746-758}
}

Figures and Tables from this paper

Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis
TLDR
A protocol for a systematic review and network meta-analysis aimed at updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression is presented.
Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
TLDR
Quetiapine and aripiprazole appear to be the most robust evidence-based options for augmentation therapy in patients with treatment-resistant depression, but clinicians should interpret these findings cautiously in light of the evidence of potential treatment-related side effects.
Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis
TLDR
Compared with other drugs, TCAs and SSRIs have the most solid evidence base for being effective in the primary care setting, but the effect size compared with placebo is relatively small.
Comparative effi cacy and tolerability of antidepressants for major depressive disorder in children and adolescents : a network meta-analysis
TLDR
A network meta-analysis was conducted for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents to identify both direct and indirect evidence from relevant trials.
Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis
TLDR
A protocol for a network meta-analysis aimed at extending results, updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of specific adverse events and tolerability in the acute treatment of major depression in adults is presented.
Effectiveness and Cost-Effectiveness of Antidepressants in Primary Care: A Multiple Treatment Comparison Meta-Analysis and Cost-Effectiveness Model
TLDR
Of the investigated antidepressants, escitalopram has the highest probability of remission and is the most effective and cost-effective pharmacological treatment in a primary care setting, when evaluated over a one year time-horizon.
...
...

References

SHOWING 1-10 OF 158 REFERENCES
Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder
TLDR
A systematic review and meta-analysis of comparative evidence for 6 SSRIs and 4 other second-generation antidepressants is conducted, examining the role of these agents in the initial treatment of ambulatory adult patients with major depressive disorder.
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
TLDR
Venlafaxine has greater efficacy than SSRIs although there is uncertainty in comparison with other antidepressants, and further studies are required to determine the clinical importance of this finding.
Double‐blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
TLDR
Although there was a numerical advantage for sertraline on several efficacy measures, there was no statistically significant difference found between the treatment groups.
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder
TLDR
A double-blind, randomized clinical trial was performed in which general practitioners and psychiatrists compared fixed doses of escitalopram with citaloprams over 8 weeks in outpatients with major depressive disorder (MDD) and confirmed that escITALopram has a superior effect in MDD.
A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
TLDR
Both mirtazapine and fluoxetine were indistinguishable in effectiveness for treatment of depressive symptoms, and both were well tolerated by the population of depressed Chinese patients.
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*
TLDR
Both duloxetine and escitalopram showed significantly greater improvement on the primary efficacy measure than placebo over the 8‑week acute treatment period, while no differences were observed between drugs or between drugs and placebo on response and remission rates at 8 weeks.
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
  • A. Schatzberg, S. Roose
  • Medicine, Psychology
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2006
TLDR
There was no significant difference in efficacy among placebo, venlafaxine, and fluoxetine for the treatment of depression in depressed patients older than 65 years.
A Double‐Blind, Randomized, Fluoxetine‐Controlled, Multicenter Study of Paroxetine in the Treatment of Depression
  • J. Tignol
  • Psychology, Medicine
    Journal of clinical psychopharmacology
  • 1993
TLDR
A marked antidepressant response and good tolerability were seen with both drugs, which further support the usefulness of paroxetine in the treatment of depressive illness.
...
...